Shares of Boston Scientific (BSX) ended the week with modest losses of 1%. The developer and marketer of medical devices announced the acquisition of Vessix Vascular on Thursday.
The Deal
Boston Scientific announced on Thursday that it will acquire privately-held Vessix Vascular. Vessix has developed a catheter-based renal denervation system for the treatment of uncontrolled hypertension.
Renal denervation is a catheter-based therapy for medication-resistant hypertension. It uses radio frequency energy to disrupt renal sympathetic nerves as hyperactivity leads to uncontrolled high blood pressure.
Read the entire article on Seekingalpha by clicking the following link
No comments:
Post a Comment